A regimen of NOAC plus P2Y12 inhibitor was associated with less TIMI major bleeding compared with VKA plus DAPT (OR 0.49; 95% CI 0.30-0.82), without a significant difference in MACE.
Meta-Analysis (n=10,026)
Does a regimen of NOAC plus P2Y12 inhibitor reduce bleeding compared to VKA plus DAPT in patients with atrial fibrillation undergoing percutaneous coronary intervention?
In patients with atrial fibrillation undergoing PCI, a dual antithrombotic regimen of a NOAC plus a P2Y12 inhibitor reduces bleeding without increasing ischemic events compared to triple therapy with a VKA and DAPT.
Odds Ratio: 0.49 (95% CI 0.3–0.82)
Importance: The antithrombotic treatment of patients with atrial fibrillation (AF) and coronary artery disease, in particular with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), poses a significant treatment dilemma in clinical practice. Objective: To study the safety and efficacy of different antithrombotic regimens using a network meta-analysis of randomized controlled trials in this population. Data Sources: PubMed, EMBASE, EBSCO, and Cochrane databases were searched to identify randomized controlled trials comparing antithrombotic regimens. Study Selection: Four randomized studies were included (n = 10 026; WOEST, PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS). Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used in this systematic review and network meta-analysis between 4 regimens using a Bayesian random-effects model. A pre hoc statistical analysis plan was written, and the review protocol was registered at PROSPERO. Data were analyzed between November 2018 and February 2019. Main Outcomes and Measures: The primary safety outcome was Thrombolysis in Myocardial Infarction (TIMI) major bleeding; secondary safety outcomes were combined TIMI major and minor bleeding, trial-defined primary bleeding events, intracranial hemorrhage, and hospitalization. The primary efficacy outcome was trial-defined major adverse cardiovascular events (MACE); secondary efficacy outcomes were individual components of MACE. Results: The overall prevalence of ACS varied from 28% to 61%. The mean age ranged from 70 to 72 years; 20% to 29% of the trial population were women; and most patients were at high risk for thromboembolic and bleeding events. Compared with a regimen of vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT; P2Y12 inhibitor plus aspirin), the odds ratios (ORs) for TIMI major bleeding were 0.58 (95% CI, 0.31-1.08) for VKA plus P2Y12 inhibitor, 0.49 (95% CI, 0.30-0.82) for non-VKA oral anticoagulant (NOAC) plus P2Y12 inhibitor, and 0.70 (95% CI, 0.38-1.23) for NOAC plus DAPT. Compared with VKA plus DAPT, the ORs for MACE were 0.96 (95% CI, 0.60-1.46) for VKA plus P2Y12 inhibitor, 1.02 (95% CI, 0.71-1.47) for NOAC plus P2Y12 inhibitor, and 0.94 (95% CI, 0.60-1.45) for NOAC plus DAPT. Conclusions and Relevance: A regimen of NOACs plus P2Y12 inhibitor was associated with less bleeding compared with VKAs plus DAPT. Strategies omitting aspirin caused less bleeding, including intracranial bleeding, without significant difference in MACE, compared with strategies including aspirin. Our results support the use of NOAC plus P2Y12 inhibitor as the preferred regimen post-percutaneous coronary intervention for these high-risk patients with AF. A regimen of VKA plus DAPT should generally be avoided.
Lópes et al. (Wed,) conducted a meta-analysis in Atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention (n=10,026). NOAC plus P2Y12 inhibitor vs. VKA plus DAPT (P2Y12 inhibitor plus aspirin) was evaluated on Thrombolysis in Myocardial Infarction (TIMI) major bleeding (OR 0.49, 95% CI 0.30-0.82). A regimen of NOAC plus P2Y12 inhibitor was associated with less TIMI major bleeding compared with VKA plus DAPT (OR 0.49; 95% CI 0.30-0.82), without a significant difference in MACE.